The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gastric Cancer Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Gastric cancer drugs are used to treat malignancies, or cancerous growths.
The global Gastric Cancer Drugs market size is expected to reach US$ 2226.9 million by 2029, growing at a CAGR of 8.9% from 2023 to 2029. The market is mainly driven by the significant applications of Gastric Cancer Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Gastric Cancer Drugs market. Doxorubicin Hydrochloride, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sunitinib segment is estimated at % CAGR for the next seven-year period.
The APAC region to account for the highest market share during the forecast period. Much of this region’s growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 45% during the forecast period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastric Cancer Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastric Cancer Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastric Cancer Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastric Cancer Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastric Cancer Drugs covered in this report include Sanofi, Eli Lilly, F. Hoffmann-La Roche, Otsuka Pharmaceutical, Novartis, Amgen, Merck, AstraZeneca and Boehringer Ingelheim, etc.
The global Gastric Cancer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi
Eli Lilly
F. Hoffmann-La Roche
Otsuka Pharmaceutical
Novartis
Amgen
Merck
AstraZeneca
Boehringer Ingelheim
Daiichi-Sankyo
Bayer HealthCare
Global Gastric Cancer Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastric Cancer Drugs market, Segment by Type:
Doxorubicin Hydrochloride
Sunitinib
Docetaxel
Mitomycin
Fluorouracil
Imatinib
Trastuzumab
Global Gastric Cancer Drugs market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Gastric Cancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Gastric Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Gastric cancer drugs are used to treat malignancies, or cancerous growths.
The global Gastric Cancer Drugs market size is expected to reach US$ 2226.9 million by 2029, growing at a CAGR of 8.9% from 2023 to 2029. The market is mainly driven by the significant applications of Gastric Cancer Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Gastric Cancer Drugs market. Doxorubicin Hydrochloride, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sunitinib segment is estimated at % CAGR for the next seven-year period.
The APAC region to account for the highest market share during the forecast period. Much of this region’s growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 45% during the forecast period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastric Cancer Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastric Cancer Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastric Cancer Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastric Cancer Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastric Cancer Drugs covered in this report include Sanofi, Eli Lilly, F. Hoffmann-La Roche, Otsuka Pharmaceutical, Novartis, Amgen, Merck, AstraZeneca and Boehringer Ingelheim, etc.
The global Gastric Cancer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi
Eli Lilly
F. Hoffmann-La Roche
Otsuka Pharmaceutical
Novartis
Amgen
Merck
AstraZeneca
Boehringer Ingelheim
Daiichi-Sankyo
Bayer HealthCare
Global Gastric Cancer Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastric Cancer Drugs market, Segment by Type:
Doxorubicin Hydrochloride
Sunitinib
Docetaxel
Mitomycin
Fluorouracil
Imatinib
Trastuzumab
Global Gastric Cancer Drugs market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Gastric Cancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Gastric Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Gastric Cancer Drugs Market Overview
1.1 Gastric Cancer Drugs Product Overview
1.2 Gastric Cancer Drugs Market Segment by Type
1.2.1 Doxorubicin Hydrochloride
1.2.2 Sunitinib
1.2.3 Docetaxel
1.2.4 Mitomycin
1.2.5 Fluorouracil
1.2.6 Imatinib
1.2.7 Trastuzumab
1.3 Global Gastric Cancer Drugs Market Size by Type
1.3.1 Global Gastric Cancer Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Gastric Cancer Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Gastric Cancer Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Gastric Cancer Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Gastric Cancer Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Gastric Cancer Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Gastric Cancer Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Gastric Cancer Drugs Sales Breakdown by Type (2018-2023)
2 Global Gastric Cancer Drugs Market Competition by Company
2.1 Global Top Players by Gastric Cancer Drugs Sales (2018-2023)
2.2 Global Top Players by Gastric Cancer Drugs Revenue (2018-2023)
2.3 Global Top Players by Gastric Cancer Drugs Price (2018-2023)
2.4 Global Top Manufacturers Gastric Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Gastric Cancer Drugs Market Competitive Situation and Trends
2.5.1 Gastric Cancer Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Gastric Cancer Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastric Cancer Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Gastric Cancer Drugs Market
2.8 Key Manufacturers Gastric Cancer Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Gastric Cancer Drugs Status and Outlook by Region
3.1 Global Gastric Cancer Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Gastric Cancer Drugs Historic Market Size by Region
3.2.1 Global Gastric Cancer Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Gastric Cancer Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Gastric Cancer Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Gastric Cancer Drugs Forecasted Market Size by Region
3.3.1 Global Gastric Cancer Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Gastric Cancer Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Gastric Cancer Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Gastric Cancer Drugs by Application
4.1 Gastric Cancer Drugs Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Gastric Cancer Drugs Market Size by Application
4.2.1 Global Gastric Cancer Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Gastric Cancer Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Gastric Cancer Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Gastric Cancer Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Gastric Cancer Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Gastric Cancer Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Gastric Cancer Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Gastric Cancer Drugs Sales Breakdown by Application (2018-2023)
5 North America Gastric Cancer Drugs by Country
5.1 North America Gastric Cancer Drugs Historic Market Size by Country
5.1.1 North America Gastric Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Gastric Cancer Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Gastric Cancer Drugs Sales in Value by Country (2018-2023)
5.2 North America Gastric Cancer Drugs Forecasted Market Size by Country
5.2.1 North America Gastric Cancer Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Gastric Cancer Drugs Sales in Value by Country (2024-2029)
6 Europe Gastric Cancer Drugs by Country
6.1 Europe Gastric Cancer Drugs Historic Market Size by Country
6.1.1 Europe Gastric Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Gastric Cancer Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Gastric Cancer Drugs Sales in Value by Country (2018-2023)
6.2 Europe Gastric Cancer Drugs Forecasted Market Size by Country
6.2.1 Europe Gastric Cancer Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Gastric Cancer Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Gastric Cancer Drugs by Region
7.1 Asia-Pacific Gastric Cancer Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Gastric Cancer Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Gastric Cancer Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Gastric Cancer Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Gastric Cancer Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Gastric Cancer Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Gastric Cancer Drugs Sales in Value by Region (2024-2029)
8 Latin America Gastric Cancer Drugs by Country
8.1 Latin America Gastric Cancer Drugs Historic Market Size by Country
8.1.1 Latin America Gastric Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Gastric Cancer Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Gastric Cancer Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Gastric Cancer Drugs Forecasted Market Size by Country
8.2.1 Latin America Gastric Cancer Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Gastric Cancer Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Gastric Cancer Drugs by Country
9.1 Middle East and Africa Gastric Cancer Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Gastric Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Gastric Cancer Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Gastric Cancer Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Gastric Cancer Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Gastric Cancer Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Gastric Cancer Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Sanofi
10.1.1 Sanofi Company Information
10.1.2 Sanofi Introduction and Business Overview
10.1.3 Sanofi Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Sanofi Gastric Cancer Drugs Products Offered
10.1.5 Sanofi Recent Development
10.2 Eli Lilly
10.2.1 Eli Lilly Company Information
10.2.2 Eli Lilly Introduction and Business Overview
10.2.3 Eli Lilly Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Eli Lilly Gastric Cancer Drugs Products Offered
10.2.5 Eli Lilly Recent Development
10.3 F. Hoffmann-La Roche
10.3.1 F. Hoffmann-La Roche Company Information
10.3.2 F. Hoffmann-La Roche Introduction and Business Overview
10.3.3 F. Hoffmann-La Roche Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 F. Hoffmann-La Roche Gastric Cancer Drugs Products Offered
10.3.5 F. Hoffmann-La Roche Recent Development
10.4 Otsuka Pharmaceutical
10.4.1 Otsuka Pharmaceutical Company Information
10.4.2 Otsuka Pharmaceutical Introduction and Business Overview
10.4.3 Otsuka Pharmaceutical Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Otsuka Pharmaceutical Gastric Cancer Drugs Products Offered
10.4.5 Otsuka Pharmaceutical Recent Development
10.5 Novartis
10.5.1 Novartis Company Information
10.5.2 Novartis Introduction and Business Overview
10.5.3 Novartis Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Novartis Gastric Cancer Drugs Products Offered
10.5.5 Novartis Recent Development
10.6 Amgen
10.6.1 Amgen Company Information
10.6.2 Amgen Introduction and Business Overview
10.6.3 Amgen Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Amgen Gastric Cancer Drugs Products Offered
10.6.5 Amgen Recent Development
10.7 Merck
10.7.1 Merck Company Information
10.7.2 Merck Introduction and Business Overview
10.7.3 Merck Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Merck Gastric Cancer Drugs Products Offered
10.7.5 Merck Recent Development
10.8 AstraZeneca
10.8.1 AstraZeneca Company Information
10.8.2 AstraZeneca Introduction and Business Overview
10.8.3 AstraZeneca Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 AstraZeneca Gastric Cancer Drugs Products Offered
10.8.5 AstraZeneca Recent Development
10.9 Boehringer Ingelheim
10.9.1 Boehringer Ingelheim Company Information
10.9.2 Boehringer Ingelheim Introduction and Business Overview
10.9.3 Boehringer Ingelheim Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Boehringer Ingelheim Gastric Cancer Drugs Products Offered
10.9.5 Boehringer Ingelheim Recent Development
10.10 Daiichi-Sankyo
10.10.1 Daiichi-Sankyo Company Information
10.10.2 Daiichi-Sankyo Introduction and Business Overview
10.10.3 Daiichi-Sankyo Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Daiichi-Sankyo Gastric Cancer Drugs Products Offered
10.10.5 Daiichi-Sankyo Recent Development
10.11 Bayer HealthCare
10.11.1 Bayer HealthCare Company Information
10.11.2 Bayer HealthCare Introduction and Business Overview
10.11.3 Bayer HealthCare Gastric Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Bayer HealthCare Gastric Cancer Drugs Products Offered
10.11.5 Bayer HealthCare Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Gastric Cancer Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Gastric Cancer Drugs Industrial Chain Analysis
11.4 Gastric Cancer Drugs Market Dynamics
11.4.1 Gastric Cancer Drugs Industry Trends
11.4.2 Gastric Cancer Drugs Market Drivers
11.4.3 Gastric Cancer Drugs Market Challenges
11.4.4 Gastric Cancer Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Gastric Cancer Drugs Distributors
12.3 Gastric Cancer Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
